Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Celldex Therapeutics, Inc.
CLDX
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.4B
$38.37
▲ +4.32%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.72 - $39.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 66.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bispecific antibody technology platform combining multiple immune mechanisms
- Strategic partnerships with Amgen, Yale University, and University of Southampton providing research validation and resources
- Experienced management team with deep expertise in antibody engineering and immunotherapy development
- Diverse pipeline addressing multiple cancer types and inflammatory conditions with differentiated mechanisms of action
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Clinical advancement of CDX-527 bispecific antibody combining CD27 costimulation with PD-L1 blockade
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.4% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CLDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 7, 2026
Reported EPS of -$1.18 vs -$1.15 consensus (-2.9% surprise). Revenue of $15.0K vs $795.4K expected (-98.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-2.9%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
-72%
+346%
-71%
-100%
-94%
-98%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.5M
$3.2M
$1.2M
$695.0K
$730.0K
$0
$75.0K
$15.0K
Margins · last 8Q
Gross
—
Profit
-524566.7%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$48.00
▲ +25.1% vs $38.37
Latest: UBS · Jun 10, 2026
2 analysts covering